Hollenberg M D, Cuatrecasas P
J Biol Chem. 1975 May 25;250(10):3845-53.
Receptors for insulin and epidermal growth factor (EGF) have been studied in confluent cultured intact human fibroblast monolayers. 125-I-EGF binds specifically to fibroblast monolayers. Half-maximal binding is observed at 4 times 10 minus 10 M EGF; at saturation of binding approximately 4 times 10-4 molecules of EGF are bound per cell. 125-I-Insulin is also bound specifically by intact monolayers with half-maximal binding observed at 10 minus 9 M insulin; about 4 times 10-3 molecules of insulin are bound per cell at saturation. Both insulin and EGF stimulate thymidine incorporation and alpha-aminoisobutyrate uptake. A half-maximal effect for insulin is observed at about 10 minus 9 M, both for the stimulation of thymidine incorporation and for the stimulation of alpha-aminoisobutyrate uptake; for EGF, half-maximal stimulation of both thymidine incorporation and alpha-aminoisobutyrate uptake is observed at 10 minus 10 M EGF. EGF causes an apparent greater stimulation of thymidine incorporation than does insulin, whereas the stimulation of alpha-aminoisobutyrate uptake is the same for both insulin and EGF. The degree of stimulation of alpha-aminoisobutyrate uptake by either insulin or EGF varied (1.2- to 2-fold) from one batch of cells to another, as did the measured values of the apparent K-m (average value 1 mM, range 0.6 to 2 mM) and V-max (average, 0.82, range 0.78 to 0.87 nmol/100 mug of protein per min) for alpha-aminoisobutyrate. Nonetheless, the apparent K-m of each peptide for stimulation of alpha-aminoisobutyrate uptake was independent of the degree of increase in alpha-aminoisobutyrate uptake, and was constant from one batch of cells to another. The peptide-mediated stimulation of alpha-aminoisobutyrate uptake can be attributed to a decrease in the apparent K-m for alpha-aminoisobutyrate (e.g. for insulin) from 0.70 to 0.57 mM; for EGF from 0.87 to 0.66 mM) and a concomitant increase in the apparent V-max for alpha-aminoisobutyrate (e.g. for insulin from 0.78 to 0.87 and for EGF from 0.80 to 0.84 nmol/min/100 mug of cell protein). The stimulation requires a 40- to 60-min period of preincubation with either peptide and is blocked by pretreating cells with cycloheximide. In the presence of ouabain, both peptides inhibit rather than stimulate alpha-aminoisobutyrate uptake; ouabain lowers the basal rate of alpha-aminoisobutyrate uptake. The uptake of 3-0-methyl-D-glucose is not affected by either EGF or insulin under conditions where insulin stimulates fat cell transport. These observations indicate that cultured human fibroblasts possess specific binding sites for insulin and EGF, which sites can be related to two actions of the peptides: stimulation of thymidine incorporation and alpha-aminoisobutyrate uptake.
在汇合培养的完整人成纤维细胞单层中对胰岛素和表皮生长因子(EGF)的受体进行了研究。125-I-EGF 特异性结合成纤维细胞单层。在 4×10⁻¹⁰ M EGF 时观察到半数最大结合;结合饱和时,每个细胞约结合 4×10⁻⁴ 个 EGF 分子。125-I-胰岛素也被完整单层特异性结合,在 10⁻⁹ M 胰岛素时观察到半数最大结合;饱和时每个细胞约结合 4×10⁻³ 个胰岛素分子。胰岛素和 EGF 均刺激胸苷掺入和α-氨基异丁酸摄取。对于胰岛素,在约 10⁻⁹ M 时观察到对胸苷掺入和α-氨基异丁酸摄取刺激的半数最大效应;对于 EGF,在 10⁻¹⁰ M EGF 时观察到对胸苷掺入和α-氨基异丁酸摄取刺激的半数最大效应。EGF 对胸苷掺入的刺激作用明显大于胰岛素,而胰岛素和 EGF 对α-氨基异丁酸摄取的刺激作用相同。胰岛素或 EGF 对α-氨基异丁酸摄取的刺激程度在不同批次的细胞间有所不同(1.2 至 2 倍),α-氨基异丁酸的表观 Km(平均值 1 mM,范围 0.6 至 2 mM)和 Vmax(平均值 0.82,范围 0.78 至 0.87 nmol/100 μg 蛋白质每分钟)的测量值也是如此。尽管如此,每种肽对α-氨基异丁酸摄取刺激的表观 Km 与α-氨基异丁酸摄取增加的程度无关,并且在不同批次的细胞间保持恒定。肽介导的α-氨基异丁酸摄取刺激可归因于α-氨基异丁酸的表观 Km 降低(例如胰岛素从 0.70 降至 0.57 mM;EGF 从 0.87 降至 0.66 mM)以及α-氨基异丁酸的表观 Vmax 相应增加(例如胰岛素从 0.78 增至 0.87,EGF 从 0.80 增至 0.84 nmol/分钟/100 μg 细胞蛋白质)。这种刺激需要与任何一种肽预孵育 40 至 六十分钟,并且用环己酰亚胺预处理细胞可阻断该刺激。在哇巴因存在下,两种肽均抑制而非刺激α-氨基异丁酸摄取;哇巴因降低α-氨基异丁酸摄取的基础速率。在胰岛素刺激脂肪细胞转运的条件下,3-0-甲基-D-葡萄糖的摄取不受 EGF 或胰岛素的影响。这些观察结果表明,培养的人成纤维细胞具有胰岛素和 EGF 的特异性结合位点,这些位点可能与肽的两种作用有关:刺激胸苷掺入和α-氨基异丁酸摄取。